Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by VINCENT TAM and Cole Hudson.
VINCENT TAM
Connection Strength
7.210
Cole Hudson
  1. Response to Yang et al. J Infect Dis. 2025 Sep 15; 232(3):e547-e548.
    View in: PubMed
    Score: 0.995
  2. Exploration of zileuton protective mechanisms against vancomycin-associated nephrotoxicity. Toxicol Appl Pharmacol. 2025 Sep 04; 505:117543.
    View in: PubMed
    Score: 0.993
  3. Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity. Antimicrob Agents Chemother. 2025 08 06; 69(8):e0028725.
    View in: PubMed
    Score: 0.982
  4. Mechanisms of gelofusine protection in an in vitro model of polymyxin B-associated renal injury. Am J Physiol Renal Physiol. 2024 Jul 01; 327(1):F137-F145.
    View in: PubMed
    Score: 0.908
  5. Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. J Antimicrob Chemother. 2023 10 03; 78(10):2435-2441.
    View in: PubMed
    Score: 0.869
  6. In vitro model to simulate multiple drugs with distinct elimination half-lives. Int J Antimicrob Agents. 2023 Oct; 62(4):106924.
    View in: PubMed
    Score: 0.855
  7. Protection against vancomycin-associated nephrotoxicity by zileuton: role of mitochondria revealed by electron microscopic study. Ultrastruct Pathol. 2025; 49(5):414-420.
    View in: PubMed
    Score: 0.247
  8. Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast. J Infect Dis. 2025 Jul 30; 232(1):191-198.
    View in: PubMed
    Score: 0.246
  9. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii. Diagn Microbiol Infect Dis. 2025 Nov; 113(3):116991.
    View in: PubMed
    Score: 0.245
  10. In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255.
    View in: PubMed
    Score: 0.229
  11. Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.
    View in: PubMed
    Score: 0.204
  12. Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates. J Chemother. 2022 09; 34(5):345-346.
    View in: PubMed
    Score: 0.191
  13. Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model. Antibiotics (Basel). 2021 Oct 16; 10(10).
    View in: PubMed
    Score: 0.190
  14. Rapid Design of Combination Antimicrobial Therapy against Acinetobacter baumannii. Comput Chem Eng. 2025 Jan; 192.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.